All Outputs (5)

Lifespan pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI (2018)
Journal Article
Xing, Y., Sapuan, A., Dineen, R., & Auer, D. P. (2018). Lifespan pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI. Movement Disorders, 33(11), 1792-1799. https://doi.org/10.1002/mds.27502

Background: Neuromelanin is a pigment with strong iron-chelating properties preferentially found in dopaminergic neurons of the substantia nigra, pars compacta (SNpc). Parkinson's disease is characterized by pronounced, MRI detectable neuromelanin lo... Read More about Lifespan pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI.

The MRI central vein marker: differentiating PPMS from RRMS and ischaemic SVD (2018)
Journal Article
Samaraweera, A. P., Falah, Y., Pitot, A., Dineen, R. A., Morgan, P. S., & Evangelou, N. (2018). The MRI central vein marker: differentiating PPMS from RRMS and ischaemic SVD. Neurology, Neuroimmunology and Neuroinflammation, 5(6), Article e496. https://doi.org/10.1212/NXI.0000000000000496

© 2018 The Author(s). Objective To determine whether the assessment of brain white matter lesion (WML) central veins differentiate patients with primary progressive MS (PPMS) from relapsing-remitting MS (RRMS) and ischemic small vessel disease (SVD)... Read More about The MRI central vein marker: differentiating PPMS from RRMS and ischaemic SVD.

Recruitment challenges in MRI studies of acute intracerebral haemorrhage: experience from the TICH-2 MRI substudy (2018)
Presentation / Conference Contribution
Pszczolkowski, S., Bath, P. M., Sprigg, N., & Dineen, R. A. (2018). Recruitment challenges in MRI studies of acute intracerebral haemorrhage: experience from the TICH-2 MRI substudy.

BACKGROUND AND AIMS Magnetic Resonance Imaging (MRI) is widely used in clinical practice and in trials for ischaemic stroke; however, relatively few large multicentre trials for intracerebral haemorrhage have used MRI. We describe the main recruitme... Read More about Recruitment challenges in MRI studies of acute intracerebral haemorrhage: experience from the TICH-2 MRI substudy.

Evaluation of an internet-based animated preparatory video for children undergoing non-sedated MRI (2018)
Journal Article
McGlashan, H. L., Dineen, R. A., Szeszak, S., Whitehouse, W. P., Chow, G., Love, A., …Wharrad, H. (2018). Evaluation of an internet-based animated preparatory video for children undergoing non-sedated MRI. British Journal of Radiology, 91(1087), Article 20170719. https://doi.org/10.1259/bjr.20170719

Objectives: We evaluate the value of an internet-based educational animated video designed to prepare children for MRI scans, and whether this video reduces scan-related anxiety in children with a neurological disorder, and healthy controls. Meth... Read More about Evaluation of an internet-based animated preparatory video for children undergoing non-sedated MRI.

Does tranexamic acid lead to changes in MRI-measures of brain tissue health in patients with spontaneous intracerebral haemorrhage? An MRI sub-study nested within the double-blind randomised controlled TICH-2 trial (2018)
Journal Article
Dineen, R. A., Pszczolkowski, S., Flaherty, K., Law, Z. K., Morgan, P. S., Roberts, I., …Sprigg, N. (in press). Does tranexamic acid lead to changes in MRI-measures of brain tissue health in patients with spontaneous intracerebral haemorrhage? An MRI sub-study nested within the double-blind randomised controlled TICH-2 trial. BMJ Open, 8(2), Article e019930. https://doi.org/10.1136/bmjopen-2017-019930

Objectives: To test whether administration of the antifibrinolytic drug tranexamic acid (TXA) in patients with spontaneous intracerebral haemorrhage (SICH) leads to increased prevalence of diffusion-weighted MRI defined hyperintense ischaemic lesions... Read More about Does tranexamic acid lead to changes in MRI-measures of brain tissue health in patients with spontaneous intracerebral haemorrhage? An MRI sub-study nested within the double-blind randomised controlled TICH-2 trial.